VERAXA Biotech Presents in vivo Proof-of-Concept Data for BiTAC®-ADC Technology at World ADC Congress
Key Highlights
- ➤BiTAC-ADCs produced strong tumor regression at a single 3 mg/kg dose.
- ➤BiTAC-ADC treatment caused no observed decrease in body weight.
- ➤Non-targeted BiTAC-ADC component showed no significant effect, supporting tumor-specific activation.
- ➤BiTAC-ADCs demonstrated comparable efficacy and differentiated safety versus conventional ADCs.
- ➤VERAXA presented first in vivo proof-of-concept data for its BiTAC-ADC platform.
Expert Statements
Christoph Erkel, Chief Scientific Officer at VERAXA
“These novel datasets on the BiTAC-ADC platform underline the rapid progress our team has made in demonstrating the potentially transformative safety benefits of BiTAC-ADCs compared to conventional ADCs.”
Christoph Erkel, Chief Scientific Officer at VERAXA
“While BiTAC-TCEs remain our priority, the rapid validation of our BiTAC-ADC concept bodes well for establishing a second pillar in our R&D and partnering strategy towards safer drugs for solid tumor patients.”
Paul Sauter, Senior Director and Department Head ADC Tech & Chemistry at VERAXA
“Demonstrating that BiTAC-ADCs can reach the tumor site following intravenous administration, induce a specific effect only upon arrival of both BiTAC components, and shrink the tumor in a living organism is a significant platform milestone and validates its underlying concept.”
ZURICH, SWITZERLAND – October 13, 2026 -- VERAXA Biotech AG (NASDAQ: VRXA; “VERAXA”), an emerging leader in designing novel cancer therapies, today presented first in vivo proof-of-concept data and additional in vitro data validating its novel BiTAC-ADC technology platform at the 17(th) World ADC Congress in San Diego, CA, USA. The in vivo data demonstrate that a systemically applied, single dose of the two-component BiTAC-ADC selectively triggered a tumor-specific response resulting in a significant reduction in tumor volume, while continuing to show differentiated safety features and the potential to overcome systemic toxicity, the primary limitation of current ADCs.
The in vivo data presented at the World ADC Congress showed that treatment with BiTAC-ADCs resulted in strong tumor regression in a xenograft breast cancer model even at a single dose of 3 mg/kg. As intended, BiTAC-ADCs utilizing one non-targeted component, thereby only delivering one component to the tumor, showed no significant effect. A control ADC, engineered by VERAXA using the same conjugation and linker-payload technology and with the same drug-antibody ratio (DAR) as its BiTAC-ADC counterpart, performed similarly. In the BiTAC-ADC treatment arm, no decrease in body weight could be observed.
Get started
Create a free account to read the full story.